NCT05007236

Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild SARS-CoV-2 Infection.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 163 (actual)
• Sponsor: Rhizen Pharmaceuticals SA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age \> 60 years, hypertension, diabetes mellitus, chronic lung disease, chronic kidney disease, liver disease, cerebrovascular disease, obesity, cancer) for developing severe Covid-19 illness.

Conditions

• SARS-CoV-2 Infection

Interventions

Type	Name	Description
DRUG	RP7214 + Standard of care (SOC)	RP7214 tablets will be administered orally twice a day for 14 days
DRUG	Placebo + Standard of care (SOC)	Placebo will be administered orally twice a for 14 days

Timeline

• Start date: 2021-09-20
• Primary completion: 2022-03-25
• Completion: 2022-03-25
• First posted: 2021-08-16
• Last updated: 2022-04-21

Locations

16 sites across 1 country: India